exacerbating MS; loss of feeling in her legs; Insomnia; Restless legs / Lost feeling in her legs; UTI; Hair falling out; New lesions; Mood up and down; Joints and knees are Weak / Increased leg weakness; loses a lot of mobility in legs; itchy throat; scratchy head; ightness in chest; eye goes blurry; double vision; eyes are not always aligned; forgetfulness; Fall; ADHD; Extreme fatigue; This spontaneous case was reported by a consumer and describes the occurrence of MULTIPLE SCLEROSIS (exacerbating MS) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Drug allergy, Drug allergy and Penicillin allergy. Concomitant products included CYANOCOBALAMIN (VITAMIN B12 [CYANOCOBALAMIN]), VITAMIN D [VITAMIN D NOS], SOLIFENACIN SUCCINATE (VESICARE), GABAPENTIN and AMFETAMINE ASPARTATE, AMFETAMINE SULFATE, DEXAMFETAMINE SACCHARATE, DEXAMFETAMINE SULFATE (ADDERALL) for an unknown indication.   On 18-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MULTIPLE SCLEROSIS (exacerbating MS) (seriousness criterion medically significant), SENSORY LOSS (loss of feeling in her legs), INSOMNIA (Insomnia), RESTLESS LEGS SYNDROME (Restless legs / Lost feeling in her legs), URINARY TRACT INFECTION (UTI), ALOPECIA (Hair falling out), SKIN LESION (New lesions), MOOD SWINGS (Mood up and down), MUSCULAR WEAKNESS (Joints and knees are Weak / Increased leg weakness), MOBILITY DECREASED (loses a lot of mobility in legs), THROAT IRRITATION (itchy throat), PRURITUS (scratchy head), CHEST DISCOMFORT (ightness in chest), VISION BLURRED (eye goes blurry), DIPLOPIA (double vision), EYE DISORDER (eyes are not always aligned), MEMORY IMPAIRMENT (forgetfulness), FALL (Fall), ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) and FATIGUE (Extreme fatigue). At the time of the report, MULTIPLE SCLEROSIS (exacerbating MS), SENSORY LOSS (loss of feeling in her legs), INSOMNIA (Insomnia), RESTLESS LEGS SYNDROME (Restless legs / Lost feeling in her legs), URINARY TRACT INFECTION (UTI), ALOPECIA (Hair falling out), SKIN LESION (New lesions), MOOD SWINGS (Mood up and down), MUSCULAR WEAKNESS (Joints and knees are Weak / Increased leg weakness), MOBILITY DECREASED (loses a lot of mobility in legs), THROAT IRRITATION (itchy throat), PRURITUS (scratchy head), CHEST DISCOMFORT (ightness in chest), VISION BLURRED (eye goes blurry), DIPLOPIA (double vision), EYE DISORDER (eyes are not always aligned), MEMORY IMPAIRMENT (forgetfulness), FALL (Fall), ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) and FATIGUE (Extreme fatigue) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 08-Jul-2021, SARS-CoV-2 antibody test: negative (Negative) negative for COVID antibodies.          Treatment medication was not reported.  Company comment: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.